XEOMIN, a new product containing the botulinum toxin, has just received FDA approval for the treatment of cervical dystonia and blepharospasm.  Clearance of the drug makes it the 3^rd product of this kind (with Botox and Dysport) to enter the U.S. market.

2 clinical trials conducted in the United States were cited during the approval process, along with comparator studies that evaluated XEOMIN in relation to Botox.

According to a study referenced in the Journal of Neurological Sciences, [XEOMIN] showed “non-inferiority” to Botox when used in equivalent doses for the treatment of blepharospasm.

So what’s the difference?  According to German manufacturer, Merz Pharmaceutical, “XEOMIN is the only botulinum toxin that does not require refrigeration prior to reconstitution. “  The company says this could “simplify product distribution and storage, and help ensure product integrity at the time of injection.”

In related news, Merz is acquiring Bioform Medical, maker of Radiesse dermal filler.

Read more on Merzusa.com

• 
• Tweet

This entry was posted on Monday, August 2nd, 2010 at 4:06 pm by newseditor and is filed under Botox and Fillers. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.